近日，海翔药业与万邦德制药正式宣布达成战略合作。此次合作旨在整合双方在医药研发、生产及市场渠道方面的优势资源，共同推进创新药物和高端仿制药的开发与商业化。根据协议，双方将在多个治疗领域展开深度协作，包括抗感染、心脑血管及肿瘤等方向，并计划联合建设符合国际标准的GMP生产基地，以提升药品质量与产能。此外，双方还将探索在海外市场拓展方面的协同机会，借助彼此的国际化布局加速产品出海进程。海翔药业在原料药和中间体领域具有深厚积累，而万邦德制药则在制剂研发和终端销售方面具备显著优势，此次强强联合有望形成从原料到制剂的一体化产业链闭环，增强整体竞争力。业内分析认为，该合作不仅有助于提升两家企业的核心竞争力，也将为中国医药行业的高质量发展注入新动能。
Recently, Hisoar Pharmaceutical and Wonbond Pharmaceutical officially announced a strategic partnership. The collaboration aims to integrate both companies’ strengths in pharmaceutical R&D, manufacturing, and market channels to jointly advance the development and commercialization of innovative drugs and high-end generic medicines. Under the agreement, the two parties will deepen cooperation across multiple therapeutic areas, including anti-infectives, cardiovascular and cerebrovascular diseases, and oncology. They also plan to co-develop a GMP-compliant production facility meeting international standards to enhance product quality and manufacturing capacity. Furthermore, the partnership will explore synergies in overseas market expansion, leveraging each other’s global footprint to accelerate international product launches. Hisoar brings extensive expertise in active pharmaceutical ingredients (APIs) and intermediates, while Wonbond excels in formulation development and downstream sales. This alliance is expected to create an integrated, end-to-end pharmaceutical value chain—from raw materials to finished dosage forms—thereby strengthening their collective competitiveness. Industry analysts believe this collaboration will not only bolster the core capabilities of both companies but also contribute fresh momentum to the high-quality development of China’s pharmaceutical sector.
原创文章，作者：admin，如若转载，请注明出处：https://ktez.cn/13096.html